文献速递系统性红斑狼疮

鉴定ST3AGL4、MFHAS1、CSNK2A2和CD226为系统性红斑狼疮相关基因座并评估SLE遗传学在药物重定位中的作用

Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning.
PubMed 文献 · Ann Rheum Dis · 2018-04-06

该研究在12 280例SLE病例和18 828例对照中开展GWAS和重复研究,鉴定出ST3AGL4、MFHAS1和CSNK2A2三个达到全基因组显著性的新基因座,并确认CD226基因座与SLE的关联。精细定位提示CSNK2A2基因座的推定因果变异位于增强子区并与B淋巴细胞中CSNK2A2表达相关;SLE风险基因更可能与已获批SLE药物的靶点蛋白相互作用(OR=2.41,p=1.50E-03),支持遗传学研究用于药物重定位。

要点

  • 鉴定出ST3AGL4(rs13238909,pmeta=4.40E-08)、MFHAS1(rs2428,pmeta=1.17E-08)和CSNK2A2(rs2731783,pmeta=1.08E-09)三个新基因座。
  • 确认CD226基因座与SLE关联(rs763361,pmeta=2.45E-08)。
  • SLE风险基因更可能与已获批SLE药物靶点相互作用(OR=2.41,p=1.50E-03)。

核心结论

  • 本研究鉴定出三个与SLE相关的新基因座,并证明SLE GWAS发现可用于药物重定位。

研究设计与样本

  • 研究纳入12 280例SLE病例和18 828例对照,开展GWAS和重复研究,并进行精细定位分析以识别新基因座内的可能因果变异。
  • 研究还扫描药物靶点数据库以评估SLE遗传学在药物重定位中的作用。

主要发现

  • 鉴定出三个超过全基因组显著性的新基因座:ST3AGL4(rs13238909,pmeta=4.40E-08)、MFHAS1(rs2428,pmeta=1.17E-08)和CSNK2A2(rs2731783,pmeta=1.08E-09)。
  • 确认CD226基因座与SLE的关联(rs763361,pmeta=2.45E-08)。
  • 精细定位和功能分析提示CSNK2A2基因座的推定因果变异位于增强子区,并与B淋巴细胞中CSNK2A2表达相关。
  • SLE风险基因更可能与已获批SLE药物的靶点蛋白相互作用(OR=2.41,p=1.50E-03)。

关键数值与推荐

  • ST3AGL4基因座rs13238909的pmeta=4.40E-08。
  • MFHAS1基因座rs2428的pmeta=1.17E-08。
  • CSNK2A2基因座rs2731783的pmeta=1.08E-09。
  • CD226基因座rs763361的pmeta=2.45E-08。
  • SLE风险基因与已获批SLE药物靶点相互作用的OR=2.41,p=1.50E-03。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Systemic lupus erythematosus (SLE) is a prototype autoimmune disease with a strong genetic component in its pathogenesis. Through genome-wide association studies (GWAS), we recently identified 10 novel loci associated with SLE and uncovered a number of suggestive loci requiring further validation. This study aimed to validate those loci in independent cohorts and evaluate the role of SLE genetics in drug repositioning. METHODS: We conducted GWAS and replication studies involving 12 280 SLE cases and 18 828 controls, and performed fine-mapping analyses to identify likely causal variants within the newly identified loci. We further scanned drug target databases to evaluate the role of SLE genetics in drug repositioning. RESULTS: We identified three novel loci that surpassed genome-wide significance, including ST3AGL4 (rs13238909, pmeta=4.40E-08), MFHAS1 (rs2428, pmeta=1.17E-08) and CSNK2A2 (rs2731783, pmeta=1.08E-09). We also confirmed the association of CD226 locus with SLE (rs763361, pmeta=2.45E-08). Fine-mapping and functional analyses indicated that the putative causal variants in CSNK2A2 locus reside in an enhancer and are associated with expression of CSNK2A2 in B-lymphocytes, suggesting a potential mechanism of association. In addition, we demonstrated that SLE risk genes were more likely to be interacting proteins with targets of approved SLE drugs (OR=2.41, p=1.50E-03) which supports the role of genetic studies to repurpose drugs approved for other diseases for the treatment of SLE. CONCLUSION: This study identified three novel loci associated with SLE and demonstrated the role of SLE GWAS findings in drug repositioning.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Wang YF, Zhang Y, Zhu Z, et al. Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus (SLE) and evaluation of SLE genetics in drug repositioning. Ann Rheum Dis. 2018. PMID: 29625966. doi:10.1136/annrheumdis-2018-213093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。